Gilead Stock Gets FDA Nod, But Investors Face Hurdle
Gilead Sciences closed at $134.36, up 2.96%, ahead of Memorial Day after the FDA cleared Hepcludex as the first U.S. treatment for chronic hepatitis delta virus. The drug won accelerated approval, with confirmatory data still pending and a boxed warning for severe relapses. U.S. markets reopen Tuesday, when Gilead will see its first trading session post-approval.
